Member Info for 0161

Will be until it corrects, I had exactly the same with my Nas shareholding being disjointed from aim.

Similar scenario loads of confusion as a corporate action happened around a price move. Markete got out of sync and the Nas market made wrong assumptions on why it should not follow the UK

It feels like it lasted for ages when the price for the same stock is so far out. But then it corrected once the confusion cleared and the price shot up something like 20% in a day to catch the UK after a good period of it being miles off it with no attempt to close the gap as we are seeing here now on aim.

If you jump over to Stocktwits the general sentiment there is that they are happy with $3 after the demerger and are now looking for it to climb up.
They don't appear to be looking over the pond at us driving our price down in mass confusion.
This has created a massive buy opportunity on aim imo.

https://stocktwits.com/message/257126163

In fact if you look at the Nasdaq candle graph it's clear to see the price movement is all around the record date set in the JP Morgan pdf.

Maybe they had some confusion on if they had to hold the day before their record which would normally be their ex date, or be holding on close of play on Friday 6th.

The price movement on these few days was close to $1, if you look at the graph the drop is only in this date range 5th to Monday 9th. Monday 9th is the date which I thought it was and has the big daily drop.

After this it's been flat and moved to where the UK price was before the vaccine panic selling here. They didnt have that panic on the Nas and the price has stayed stable, hence the gap.

On aim we haven't closed the gap, as we think they are pricing in Accustem, I think this is the confusion. As I say it has happened before when one market is confused about the other.

For me the drop from $3.80/$4 to the current price of $3 which happened between the 5th and 9th reflects the demerger.
Aim moving down to 86p on vaccine news and the Nas staying flat around $3 is what has created the gap in the market and the confusion around the demerger is keeping it there for now.

Could be a really quick correction at some point, it's happened before the other way round, gla

Looking on Stocktwits there have been a good few posts over the last few weeks by different posters who all believe that the demerger is over and that their price already reflects this. Based of this the sentiment doesn't appear to be that the buys on the American market think it's because the Accustem demerger hasn't happened for them, the UK is just valuing Tiziana lower and th sentiment on the Nas doesn't agree. Also we are lower on aim as we crashed down on vaccine news, the Nasdaq price was unfazed by this which is what is responsible for the current gap in the prices imo.

Back when there was the ADR split on the Nas the same confusion was present as we are seeing now on aim. There was a gap of around 20% as the Nas traded much lower than aim. It had a big gap between markets for a good few days, then eventually the markets aligned in a day seeing the Nas shoot up to meet the UK market.

This time it's the other way around and it's aim that's below the Nas, hopefully we will see the same snap correction.

Doesn't clear it up as it depends if it's a significant div e.g over 25% , but well worth a read and covers enrolment being passed on shares sold after record but before ex date.
Looks like it's either day before record date , or a tbc ex date, it's all good fun :)

https://www.investor.gov/introduction-investing/investing-basics/glossary/ex-dividend-dates-when-are-you-entitled-stock-and

Y-alam , I did think it was close of play on the record date on that doccument, leaving just the payment date tbc as they can't pay shares when their is no adr setup etc on the Nas.

The document is not clear and their is no mention of an ex date on the document only an actual payment date to be confirmed. Wolf could well be right, I am just as confused as everyone else now.

The right answer does make a big difference, if I was right originally then the Nas is not trading +25p because of Accustem.
If Wolf is right and the ex date is going to be announced as well as the payment date then it means buying now or anytime before an in set date means you get more Accustem shares.

It really is a mess, the ADR was the same and it's worth noting that shareholders on the Nas were very confused and the price jumped 20% to correct in the afternoon when the "clear things up" RNS was released at the last minute.

Legal wolf, mud is clearer haha.
We would normally expect to see a record date, and ex date... Instead we have a "foreign record date" , record date, and "payment date" which is the only one with an uncertain date.
My guess was that you have to hold between the first record date and close of play on the 2nd record date. If its the payment date that is the ex date then it means we can get double accustem shares by selling on aim and buying on the Nasdaq as if the ex date hasn't passed on the Nas it doesn't matter that that the record date has passed as the entitlment will transfer to the purchaser prior to the ex date.

Very very messy, similar to the adr change when the effective date was before the ex date. I called the nomad and JP Morgan at the time and the nomad looked in to it and called me back to say they didn't know. JP Morgan apparently did know when I called but it turned out they got it wrong. I also emailed tiziana but they never replied but released an RNS later that day that clarified it and turned out to be the opposite of what JP had advised.

So from previous experience it's very hard to figure out what's what.

The timetable did get released by JP Morgan

https://api.markitdigital.com/jpmadr-public/v1/cms/document?cmsId=80119e4a885748449322bda9a6e3741d

JP Morgan time table is here
https://api.markitdigital.com/jpmadr-public/v1/cms/document?cmsId=80119e4a885748449322bda9a6e3741d

Although they date call it an ex date , it looks like you had to be on the register on the first date and still be holding now as it's says close of business Friday.

I suspect that if you purchased on Thursday although not entitled as you didn't own on the "foreign record date" the benefit would be transfered to you as the seller didn't hold, plus otherwise there would then be less accu shares than tiziana shares, so they have to go somewhere.

I think a lot of people didn't see the JP timetable and sold yesterday by mistake, plus the Nas got excited about the Bloomberg interview about the Brasil trial this week so it's very hard to guess a value or Accustem based on the two prices. I think pocket it and time will tell, Tiziana and the Brazil trial is what matters until then. There is a lot of noise around monoclonal antibodies but not much effect on our price yet.

The fact that our monoclonal antibody is fully human and nassal has big advantages over all the other companies scrambling to use mabs.

1. Nassal means the dose can be lower as it's direct to site, mabs are hard to make and very expensive so this is huge if you want to treat the world.
2. IV adds tremendous cost, which is avoided with ours.
3. If needed as it's fully human ours is probably the only monoclonal antibody where the dose can be increased safely if required to get a response.

It does look like monoclonal antibodies are our best bet to treat covid, and it's hard to see any company that has a stronger position, the only disadvantage is that we only have CD3, however this was used in trump's ****tail.

Looks like adr shares had to be held at close of business today, so any sold before lose accu

https://api.markitdigital.com/jpmadr-public/v1/cms/document?cmsId=80119e4a885748449322bda9a6e3741d

With the suspensetion of the Lilly trial I google searched to see if the 3 companies showed up for investors looking for companies to invest in which are trialing mabs to treat covid.

The other two show up, Tiziana is nowhere to be seen.

It made me think how many investors are searching to invest in companies with a mabs trial and finding our two competitors and nothing on tiziana?
Especially this week given the problems Lilly have had.

Is it worthwhile and even legal to promote tiziana using Google AdWords to get our presence ?

And directing them to this
https://www.proactiveinvestors.co.uk/companies/news/925603/tiziana-life-sciences--very-excited--about-potential-for-nasal-delivery-of-foralumab-for-coronavirus-925603.html

With Bill Gates recent interview and now the news from NIAID there appears to be a strong focus on monoclonal antibodies - mAbs for treating covid.
https://www.nih.gov/news-events/news-releases/clinical-trials-monoclonal-antibodies-prevent-covid-19-now-enrolling?utm_source=dlvr.it&utm_medium=twitter

Given this strong move towards monoclonal antibodies isnt it strange that their isn't more attention on Tiziana as it appears they have a unique advantage being the only company with a fully human mAbs, not to mention lots of IP around this.
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-submission-patent-application-foralumab

Although Tiziana have so much to offer besides Covid19 the increasing interest in mAbs appears not to have been picked up in relation to Tiziana's Foralumab and patents.
Any ideas why?

As Tiziana is dual listed do the holders of the American listed stock get voting rights under the ADR ? Also are they guaranteed the free shares in Accustem in the same way as a UK holder ? ... Assuming it gets voted in ??

Anybody know how ADR shares work in a demerger ? as the US stock looks to be slightly better value.
Or is it slightly lower due to this uncertainty?

Might be a good opportunity for a late top-up

Sanofi has been clear in its plans to set a new course under the leadership of its English chief executive. Alongside deprioritising diabetes and cardiovascular products, Mr Hudson has said the group will now focus on the more lucrative areas of oncology and rare diseases.
https://www.google.com/amp/s/www.evaluate.com/node/15872/amp

Coincidentally not long after Tiziana announced their oncology product stemprintER significantly outperforms the market leader, Sanofi freed up billions.

I might be connecting dots that are not there, but one of the world's largest pharmaceutical companies is about to invest a lot of money in oncology to play catch up in their words.

Wiederschain said molecular oncology, which targets a tumor based on its genetic makeup, would also be a future differentiator.
https://www.google.com/amp/s/uk.mobile.reuters.com/article/amp/idUKKBN1JG0GR

It has also been looking to acquisitions to fill its pipeline.

Do your research people, I don't expect to ever find an opportunity as good as this again. Amazingly all the research is there just not an RNS and the share price is under £1 hahaha gla

I ran a creditsafe report on the new company that Stims found Accustem Sciences

The 100% shareholder is indeed Tiziana Life Sciences.
This company alone holding stemprintER is worth more than today's share price imo
It means either commercialisation of the product or a split to aid the sale such as the 2.8billion accusation by exact sciences of the products that this replaces